Objective: Our purpose was to investigate associations between different cognitive profiles and their underlying functional brain changes as measured by electroencephalogram (EEG) in Alzheimer’s disease (AD). Methods: EEG was obtained and neuropsychological performance assessed in 254 patients with AD. The EEGs were visually assessed for the presence of focal and/or diffuse abnormalities. Multivariate analysis of variance for repeated measures was performed with presence of focal and/or diffuse abnormalities as between-subjects factor and neuropsychological tests as within-subject factor. Age, sex and education were entered as covariates. Results: Twenty-eight percent of the patients had a normal EEG, 32% had focal abnormalities, 14% diffuse abnormalities and 26% had both focal and diffuse abnormalities. Patients with a normal EEG presented with a cognitive profile in which memory was mostly impaired. Patients with focal and diffuse EEG abnormalities presented with a nonmemory profile. Conclusion: These results illustrate that specific types of EEG abnormalities are associated with different cognitive profiles in AD, providing biological support in terms of brain functioning for variability in cognitive impairment.

Keywords:
Alzheimer’s disease, EEG, Dementia, cognition
1.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
2.
Galton CJ, Patterson K, Xuereb JH, Hodges JR: Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000;123:484–498.
3.
Van der Flier WM, Schoonenboom SN, Pijnenburg YA, Fox NC, Scheltens P: The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006;67:526–527.
4.
Schott JM, Ridha BH, Crutch SJ, Healy DG, Uphill JB, Warrington EK, Rossor MN, Fox NC: Apolipoprotein e genotype modifies the phenotype of Alzheimer disease. Arch Neurol 2006;63:155–156.
5.
Stopford CL, Snowden JS, Thompson JC, Neary D: Variability in cognitive presentation of Alzheimer’s disease. Cortex 2008;44:185–195.
6.
Jeong J: EEG dynamics in patients with Alzheimer’s disease. Clin Neurophysiol 2004;115:1490–1505.
7.
Jelic V, Kowalski J: Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci 2009;40:129–142.
8.
Erkinjuntti T, Larsen T, Sulkava R, Ketonen L, Laaksonen R, Palo J: EEG in the differential diagnosis between Alzheimer’s disease and vascular dementia. Acta Neurol Scand 1988;77:36–43.
9.
Liedorp M, van der Flier WM, Hoogervorst EL, Scheltens P, Stam CJ: Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dement Geriatr Cogn Disord 2009;27:18–23.
10.
Schreiter GU, Rousson V, Hentschel F, Sattel H, Gasser T: Alzheimer disease versus mixed dementias: an EEG perspective. Clin Neurophysiol 2008;119:2255–2259.
11.
Hughes JR, Shanmugham S, Wetzel LC, Bellur S, Hughes CA: The relationship between EEG changes and cognitive functions in dementia: a study in a VA population. Clin Electroencephalogr 1989;20:77–85.
12.
Klass DW, Brenner RP: Electroencephalography of the elderly. J Clin Neurophysiol 1995;12:116–131.
13.
Kowalski JW, Gawel M, Pfeffer A, Barcikowska M: The diagnostic value of EEG in Alzheimer disease: correlation with the severity of mental impairment. J Clin Neurophysiol 2001;18:570–575.
14.
Schreiter-Gasser U, Gasser T, Ziegler P: Quantitative EEG analysis in early onset Alzheimer’s disease: correlations with severity, clinical characteristics, visual EEG and CCT. Electroencephalogr Clin Neurophysiol 1994;90:267–272.
15.
Van der Hiele K, Vein AA, van der Welle A, van der Grond J, Westendorp RG, Bollen EL, van Buchem MA, van Dijk JG, Middelkoop HA: EEG and MRI correlates of mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 2007;28:1322–1329.
16.
Claus JJ, Kwa VI, Teunisse S, Walstra GJ, van Gool WA, Koelman JH, Bour LJ, Ongerboer der V: Slowing on quantitative spectral EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:167–174.
17.
Van der Hiele K, Vein AA, Reijntjes RH, Westendorp RG, Bollen EL, van Buchem MA, van Dijk JG, Middelkoop HA: EEG correlates in the spectrum of cognitive decline. Clin Neurophysiol 2007;118:1931–1939.
18.
Helkala EL, Laulumaa V, Soikkeli R, Partanen J, Soininen H, Riekkinen PJ: Slow-wave activity in the spectral analysis of the electroencephalogram is associated with cortical dysfunctions in patients with Alzheimer’s disease. Behav Neurosci 1991;105:409–415.
19.
Verhage F: Intelligence and Age: Study with Dutch People Aged 12–77 (in Dutch). Assen, Van Gorcum, 1964.
20.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
21.
Lindeboom J, Matto D: Cijferreeksen en Knox blokken als concentratietests voor ouderen (in Dutch). T Gerontol Geriat 1994;25:63–68.
22.
Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C: Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73:126–133.
23.
Reitan R: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271–276.
24.
Rae-Grant A, Blume W, Lau C, Hachinski VC, Fisman M, Merskey H: The electroencephalogram in Alzheimer-type dementia: a sequential study correlating the electroencephalogram with psychometric and quantitative pathologic data. Arch Neurol 1987;44:50–54.
25.
Pucci E, Belardinelli N, Cacchio G, Signorino M, Angeleri F: EEG power spectrum differences in early and late onset forms of Alzheimer’s disease. Clin Neurophysiol 1999;110:621–631.
26.
De Waal H, Stam CJ, Blankenstein MA, Pijnenburg YA, Scheltens P, van der Flier WM: EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2010, Epub ahead of print.
27.
Van der Vlies AE, Pijnenburg YA, Koene T, Klein M, Kok A, Scheltens P, van der Flier WM: Cognitive impairment in Alzheimer’s disease is modified by APOE genotype. Dement Geriatr Cogn Disord 2007;24:98–103.
28.
Petersen RC, Jack CR Jr, Xu YC, Waring SC, O’Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Boeve BF, Kokmen E: Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000;54:581–587.
29.
Sluimer JD, Vrenken H, Blankenstein MA, Fox NC, Scheltens P, Barkhof F, van der Flier WM: Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008;70:1836–1841.
30.
Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S, Rabinovici GD, Miller BL, Gorno-Tempini ML: Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009;73:1571–1578.
31.
Karas G, Sluimer J, Goekoop R, van der FW, Rombouts SA, Vrenken H, Scheltens P, Fox N, Barkhof F: Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol 2008;29:944–949.
32.
Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC: Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2009, Epub ahead of print.
33.
Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, Mori E: Apolipoprotein E ε 4 and the pattern of regional brain atrophy in Alzheimer’s disease. Neurology 2001;57:1461–1466.
34.
Gutierrez-Galve L, Lehmann M, Hobbs NZ, Clarkson MJ, Ridgway GR, Crutch S, Ourselin S, Schott JM, Fox NC, Barnes J: Patterns of cortical thickness according to APOE genotype in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009;28:476–485.
35.
Geroldi C, Pihlajamaki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB: APOE-ε4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825–1832.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.